Skip to search boxSkip to navigationSkip to main content

Chronic constipation

  • Michael Camilleri(corresponding author)
    ,
  • Alexander C. Ford
    ,
  • Gary M. Mawe
    ,
  • Phil G. Dinning
    ,
  • ,
  • William D. Chey
*Corresponding author for this work
  • Mayo Clinic Rochester, MN
    ,
  • St James's University Hospital
    ,
  • University of Vermont
    ,
  • Flinders University
    ,
  • ,
  • University of Michigan, Ann Arbor
Scholary Output:
Contribution to journal
Review article
Peer-review

Abstract

Chronic constipation is a prevalent condition that severely impacts the quality of life of those affected. Several types of primary chronic constipation, which show substantial overlap, have been described, including normal-transit constipation, rectal evacuation disorders and slow-transit constipation. Diagnosis of primary chronic constipation involves a multistep process initiated by the exclusion of 'alarm' features (for example, unintentional weight loss or rectal bleeding) that might indicate organic diseases (such as polyps or tumours) and a therapeutic trial with first-line treatments such as dietary changes, lifestyle modifications and over-the-counter laxatives. If symptoms do not improve, investigations to diagnose rectal evacuation disorders and slow-transit constipation are performed, such as digital rectal examination, anorectal structure and function testing (including the balloon expulsion test, anorectal manometry or defecography) or colonic transit tests (such as the radiopaque marker test, wireless motility capsule test, scintigraphy or colonic manometry). The mainstays of treatment are diet and lifestyle interventions, pharmacological therapy and, rarely, surgery. This Primer provides an introduction to the epidemiology, pathophysiological mechanisms, diagnosis, management and quality of life associated with the commonly encountered clinical problem of chronic constipation in adults unrelated to opioid abuse.

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Peer-review

Original language

English (US)

Article number

17095

Journal (Volume, Issue Number)

Nature Reviews Disease Primers (Volume 3)

Publication milestones

  • Published - 12/14/2017

Publication status

Published - 12/14/2017

Publication IDs

  • Scopus: 85038418414
  • PubMed: 29239347

Publication metrics

Metrics

SciVal
citations
73
SciVal
FWCI
5.18
SciVal
Author count
10
SciVal
Paper percentile
98
SciVal
Top percentile
5
Scopus
citations
Fractional count
1
Fractional count
0.10
Fractional count
9
Fractional count
0.90
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
357
Citation count
374

Funding Details

M.C. serves on an advisory board for Ironwood Pharmaceuticals and Shire Pharmaceuticals, with compensa‑ tion to his employer and not to him personally, and has received grant and research support from NGM Pharma‑ ceuticals. A.C.F. has received grant and research support from Almirall and has acted as a consultant and speaker for Almirall, Norgine and Shire Pharmaceuticals. S.S.R. serves on the advisory board for Forest Labs, Salix Pharmaceuticals, Takeda Pharmaceuticals and Synergy Pharmaceuticals and has received research grants from Forest Labs and Medtronic Corporation. M.S. has received grant and research support from Danone Nutricia Research and Ferring Pharmaceuticals and has acted as a consultant and speaker for Allergan, Almirall, Danone Nutricia Research, Menarini, Nestlé, Shire Pharmaceuticals, Takeda Pharmaceuticals and Tillotts. L.C. has served on advisory boards for BioAmerica, Cairn Diagnostics, IM Healthcare Science LLC, Napo Pharma‑ ceuticals, Salix Pharmaceuticals, and Synergy Pharma‑ ceuticals. All other authors have no relevant conflicts of interest related to the content of this Primer to declare. This study was supported in part by the US Public Health Service NIH Grant 5R21DK104127‑02 and Grant 1 U34 DK109191‑01 to S.S.R. The authors thank C. L. Stanislav (Mayo Clinic, USA) for her excellent administrative support.
FundersFunding numbers
Danone Nutricia Research and Ferring Pharmaceuticals
-
Danone Nutricia Research, Menarini, Nestlé
-
Tillotts Pharma
-
US Public Health Service NIH
1 U34 DK109191‑01, 5R21DK104127‑02
TPUSA
-
Shire
-